Loading company…
Nucleix, based in Rehovot, Israel, develops non-invasive diagnostic tests for early cancer detection, including Bladder EpiCheck.
Its Bladder EpiCheck test detects primary and recurrent bladder cancer and upper tract urinary cancer, with CE marking in Europe and FDA clearance for monitoring recurrence in the United States. Founded in 2008 by Adam Wasserstrom and Danny Frumkin, the company has raised USD 22.00 mn in total funding, with its latest round led by Sands Capital Ventures. It has completed 6 deals since inception and is at the Seed stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in